Ultragenyx Angelman syndrome drug fails Phase 3 trial endpoints

September 2, 2026 4:01 PM

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that its Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome failed to meet ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found